Asset Details
Do you wish to reserve the book?
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
Do you wish to request the book?
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells
2018
Overview
Background
Chimeric antigen receptor-engineered T (CAR-T) cells have extraordinary effect in treating lymphoblastic leukemia. However, treatment of acute myeloid leukemia (AML) using CAR-T cells remains limited to date. Leukemogenesis always relates with the abnormalities of cytogenetics, and nearly one third of AML patients have activating mutations in Fms-like tyrosine kinase 3 (FLT3) which reminded poor prognosis. Considering the FLT3 expressed in AML patients’ blast cells, it may be a new candidate target for CAR-T therapy to treat FLT3
+
AML, especially patients harboring FLT3-ITD mutation.
Methods
The FLT3L CAR-T using FLT3 ligand as recognizing domain was constructed. The specific cytotoxicity against FLT3
+
leukemia cell lines, primary AML cells, and normal hematopoietic progenitor stem cells (HPSCs) in vitro were evaluated. In addition, FLT3
+
AML mouse model was used to assess the effect of FLT3L CAR-T therapy in vivo.
Results
FLT3L CAR-T cells could specifically kill FLT3
+
leukemia cell lines and AML patients’ bone marrow mononuclear cells in vitro (with or without FLT3 mutation) and have more potent cytotoxicity to FLT3-ITD cells. In a human FLT3
+
AML xenograft mouse model, FLT3L CAR-T cells could significantly prolong the survival of mice. Furthermore, it was found that FLT3L CAR-T cells could activate the FLT3/ERK signaling pathway of FLT3
+
leukemia cells with wild-type FLT3; meanwhile, it had no inhibitory effects on the colony formation of CD34
+
stem cells derived from normal human umbilical cord blood.
Conclusions
The ligand-based FLT3L CAR-T cells could be a promising strategy for FLT3
+
AML treatment, especially those carried FLT3 mutation.
Publisher
BioMed Central,BioMed Central Ltd,BMC
